| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B |
| Entrez GeneID | 23495 |
| clone | 1F6B3 |
| WB Predicted band size | 31.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD267 (AA: extra(1-165)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD267(TACI)抗体的参考文献示例，包括文献名称、作者及摘要概述：
1. **文献名称**：*Targeting TACI in Systemic Lupus Erythematosus: A Novel Therapeutic Approach*
**作者**：Dörner T. 等
**摘要**：研究探讨了抗CD267(TACI)抗体在系统性红斑狼疮(SLE)模型中的治疗潜力。结果显示，抗体通过抑制过度活跃的B细胞信号通路，减少自身抗体产生，缓解了疾病症状。
2. **文献名称**：*Anti-TACI Antibody Enhances Myeloma Cell Apoptosis via Synergistic Signaling Blockade*
**作者**：Tai Y.T. 等
**摘要**：该文献报道了抗CD267抗体在多发性骨髓瘤治疗中的应用。实验表明，抗体通过阻断BAFF/APRIL-TACI信号轴，增强肿瘤细胞凋亡，并与蛋白酶体抑制剂发挥协同作用。
3. **文献名称**：*Structural Insights into TACI Recognition by Therapeutic Antibodies*
**作者**：Kim H.M. 等
**摘要**：通过X射线晶体学解析了抗CD267抗体与TACI的复合物结构，揭示了抗体结合表位的关键区域，为优化靶向TACI的抗体药物设计提供了结构基础。
4. **文献名称**：*TACI as a Biomarker in Primary Immunodeficiency Disorders*
**作者**：Salzer U. 等
**摘要**：研究评估了CD267(TACI)表达水平在常见变异型免疫缺陷病(CVID)中的诊断价值，发现TACI抗体检测有助于识别特定患者亚群，指导个体化治疗。
**注**：以上文献信息为示例性质，建议通过PubMed或Google Scholar以“CD267 antibody”“TACI therapeutic”等关键词检索最新研究，以获取准确文献信息。
The CD267 antibody targets the CD267 antigen, also known as TACI (Transmembrane Activator and CAML Interactor), encoded by the TNFRSF13B gene. TACI is a type II transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It plays a critical role in B-cell immunity by binding to ligands APRIL (a proliferation-inducing ligand) and BAFF (B-cell activating factor), which regulate B-cell activation, differentiation, and antibody production. Dysregulation of TACI signaling is linked to immune disorders, including common variable immunodeficiency (CVID) and autoimmune diseases like systemic lupus erythematosus (SLE).
CD267 antibodies are primarily used in research to study TACI's function in immune regulation and disease pathogenesis. They enable detection of TACI expression in B-cells via techniques like flow cytometry, immunohistochemistry, and Western blotting. Therapeutic applications are emerging, with anti-TACI antibodies explored for treating B-cell malignancies and autoimmune conditions by modulating ligand-receptor interactions. Some antibody-based therapies aim to block excessive BAFF/APRIL signaling, which is implicated in abnormal B-cell survival. Additionally, CD267 antibodies serve as tools in drug development, aiding in the evaluation of candidate molecules targeting TACI pathways. Their role in diagnostic assays for monitoring immune disorders is also under investigation.
×
